Leaders of the 23-county Florida High Tech Corridor today shared the stage at Synapse Summit 2022 where they celebrated a 25-year legacy of partnership and innovation and unveiled a commitment to “unleash the region’s expotential.”
UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
With a record $121 million awarded to the University of Florida College of Medicine from the National Institutes of Health in 2021, the medical school reached the top 25 in NIH funding among public universities.
A new study published in Frontiers by faculty at UF/IFAS Florida Medical Entomology finds that Culex mosquitoes prefer to feed on lizards. This finding might help researchers find ways to reduce the number of West Nile-carrying mosquitoes within an ecosystem.
Diseases impact different populations in different ways. Despite this, the samples used for medical research are often not representative of diverse populations. That disparity is at the heart of the studies conducted by Drs. Josephine Allen and Erika Moore.
Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years.
Digital fitness and wellness company FitOn has raised $40 million in Series C funding led by Delta-v Capital, the company announced on Tuesday. FitOn is also expanding its reach in wellness by acquiring Tampa-based corporate wellness platform Peerfit, a UF startup that incubated at UF Innovate | Accelerate at The Hub.
The U.S. Department of Defense (DOD) has awarded UF startup Ology Bioservices, Inc. (Ology), a wholly-owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).